Prana Biotechnology (NASDAQ: PRAN) Shares Surge on FDA Ruling: U.S. Daily Market Movers

Published:

Small
cap stocks making big moves on Friday, September 5, 2014 (as of 4 pm EST), as
reported by Sean Mason, SmallCapPower.com

Prana Biotechnology (NASDAQ: PRAN)
shares shot up 19% to $2.54 on volume of more than 16.4 million shares Friday
after the company announced that the U.S. Food and Drug Administration (FDA)
has granted Orphan Drug designation to PBT2 for the treatment of Huntington
Disease.

As well,
shares of Recro Pharma, Inc. (NASDAQ: REPH)
plunged 46% to $3.09 on more than 1.6 million shares traded as the specialty
pharmaceutical company said its Phase 2b clinical trial of Dex-IN for the treatment
of acute post-operative pain is not expected to reach statistical significance
at its current design.

Intellipharmaceutics International Inc. (NASDAQ: IPCI)
stock, meanwhile, popped 16% to $3.14 after its shares received an upgrade from
‘hold’ to ‘buy’ at Maxim Group.

Finally, Quiksilver, Inc. (NYSE: ZQK)
shares sank 25% to $2.13 after the outdoor sports apparel retailer reported third-quarter
results that fell short of Wall Street expectations. 

Related articles

Recent articles